After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.

As it completed its takeover of Xellia’s finished dosage form business and related assets, Hikma set out how it expects its injectables business to benefit from the acquisition.

In an amicus brief filed in support of Hikma over its US skinny-label generic dispute with Amarin, local industry association the AAM warned that the indication carve-out process that “began as a shield” has now “become a sword that is being wielded against the very generics the law was intended to protect.”